Adicet Bio, Inc. (ACET)

$1.11

-0.07

(-5.93%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Adicet Bio, Inc.

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 82.5% return, outperforming this stock by 176.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 26.6% return, outperforming this stock by 117.7%

Performance

  • $1.10
    $1.18
    $1.11
    downward going graph

    0.89%

    Downside

    Day's Volatility :6.77%

    Upside

    5.93%

    downward going graph
  • $1.10
    $20.88
    $1.11
    downward going graph

    0.9%

    Downside

    52 Weeks Volatility :94.73%

    Upside

    94.68%

    downward going graph

Returns

PeriodAdicet Bio, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-36.21%
-3.9%
0.0%
6 Months
-80.21%
1.7%
0.0%
1 Year
-93.75%
-4.5%
-3.7%
3 Years
-91.0%
18.5%
-4.7%

Highlights

Market Capitalization
50.9M
Book Value
$4.52
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.35
PEG Ratio
0.82
Wall Street Target Price
15.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.21%
Return On Equity TTM
-55.84%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
25.0M
EBITDA
-127.1M
Diluted Eps TTM
-3.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.26
EPS Estimate Next Year
-1.99
EPS Estimate Current Quarter
-0.74
EPS Estimate Next Quarter
-0.72

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Adicet Bio, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1311.71%

Current $1.11
Target $15.67

Technicals Summary

Sell

Neutral

Buy

Adicet Bio, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adicet Bio, Inc.
Adicet Bio, Inc.
-9.92%
-80.21%
-93.75%
-91.0%
-91.55%
Seagen, Inc.
Seagen, Inc.
0.13%
10.39%
82.47%
25.75%
240.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.02%
9.96%
8.84%
55.25%
122.81%
Moderna, Inc.
Moderna, Inc.
5.55%
-37.86%
-54.85%
-48.81%
320.32%
Novo Nordisk A/s
Novo Nordisk A/s
5.22%
29.99%
67.17%
209.46%
341.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.91%
6.68%
9.71%
52.38%
93.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adicet Bio, Inc.
Adicet Bio, Inc.
NA
NA
0.82
-1.26
-0.56
-0.28
0.0
4.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adicet Bio, Inc.
Adicet Bio, Inc.
Buy
$50.9M
-91.55%
NA
0.0%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
240.59%
NA
-32.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
122.81%
22.78
30.47%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
320.32%
24.73
-38.0%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
341.77%
43.04
35.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
93.39%
26.52
35.94%

Institutional Holdings

  • Orbimed Advisors, LLC

    19.32%

  • RTW INVESTMENTS, LLC

    9.85%

  • COWEN AND COMPANY, LLC

    6.30%

  • TANG CAPITAL MANAGEMENT LLC

    5.76%

  • Morgan Stanley - Brokerage Accounts

    5.68%

  • BlackRock Inc

    5.54%

Corporate Announcements

  • Adicet Bio, Inc. Earnings

    Adicet Bio, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v

Organization
Adicet Bio, Inc.
Employees
132
CEO
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
Industry
Distribution Services

Discover More

FAQs